Adipose-derived Stem Cell Conditioned Media Extends Survival time of a mouse model of Amyotrophic Lateral Sclerosis by Fontanilla, Christine V. et al.
1Scientific RepoRts | 5:16953 | DOI: 10.1038/srep16953
www.nature.com/scientificreports
Adipose-derived Stem Cell 
Conditioned Media Extends 
Survival time of a mouse model of 
Amyotrophic Lateral Sclerosis
Christine V. Fontanilla1,*, Huiying Gu1,*, Qingpeng Liu2,*, Timothy Z. Zhu1, Changwei Zhou2, 
Brian H. Johnstone3, Keith L. March3, Robert M. Pascuzzi1, Martin R. Farlow1 & 
Yansheng Du1
Adipose stromal cells (ASC) secrete various trophic factors that assist in the protection of neurons 
in a variety of neuronal death models. In this study, we tested the effects of human ASC conditional 
medium (ASC-CM) in human amyotrophic lateral sclerosis (ALS) transgenic mouse model expressing 
mutant superoxide dismutase (SOD1G93A). Treating symptomatic SOD1G93A mice with ASC-CM 
significantly increased post-onset survival time and lifespan. Moreover, SOD1G93A mice given ASC-CM 
treatment showed high motor neuron counts, less activation of microglia and astrocytes at an 
early symptomatic stage in the spinal cords under immunohistochemical analysis. SOD1G93A mice 
treated with ASC-CM for 7 days showed reduced levels of phosphorylated p38 (pp38) in the spinal 
cord, a mitogen-activated protein kinase that is involved in both inflammation and neuronal death. 
Additionally, the levels of α-II spectrin in spinal cords were also inhibited in SOD1G93A mice treated 
with ASC-CM for 3 days. Interestingly, nerve growth factor (NGF), a neurotrophic factor found in 
ASC-CM, played a significant role in the protection of neurodegeneration inSOD1G93A mouse. These 
results indicate that ASC-CM has the potential to develop into a novel and effective therapeutic 
treatment for ALS.
Amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease, is defined by progressive 
loss of motor neurons, resulting in paralysis and ultimately death. The process is generally takes 2 to 5 
years after diagnosis1. The degeneration of motor neurons in the spinal cord results in muscle atrophy 
and paralysis2. There are about two ALS incidences per 100,000 persons in the United States annually3. 
The majority cases are sporadic in origin and 5–10% are familial (FALS)4. Not only are both cases highly 
similar in clinical course, pathophysiology, and outcome, the mechanisms underlying disease progres-
sion are also posited to be the same5. 15–20% FALS are linked to mutant Zn/Cu superoxide dismutase6,7 
(SOD1), which led to the creation of SOD1G93A mouse model. SOD1G93A mouse is currently the most 
extensively studied animal model of ALS8,9 that exhibit the major hallmarks of ALS, which include motor 
neuron pathology and progressive paralysis8,9. Researchers using this model has discovered an array of 
processes from ALS onset to end, including glutamate excitotoxicity, glial cell activation, oxidative dam-
age, neuroinflammation, aberrant protein folding, mitochondrial dysfunction and axonal transport4,10.
Oxidative stress and motor neuron excitotoxic death have been linked to neuroinflammatory 
responses, for example, elevations of pro-inflammatory cytokines in the CNS11,12, astrocyte13 and 
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microglia activation14. These pathogenic hallmarks are thought to play key roles in motor neuron death 
and ALS progression.
It has been reported that p38 mitogen activated protein kinase (MAPK) are involved in the motor 
neuron death15–17. Phosphorylated p38 MAPK was increased in the spinal cords of SOD1G93A mice15,16,18 
and human ALS patients19. Moreover, the inhibition of p38 MAPK pathway extended motor neuron 
survival and also decreased the activation of microglial in ALS mouse spinal cord17, this suggests that 
the pathogenic aspect of p38 MAPK pathway play a significant role in ALS motor neuron cell death and 
neuroinflammation.
Activity of the Ca2+-activated protease, calpain, has also been observed to be increased in the SOD1G93A 
mouse20,21 due to increased levels of calcium in the cytosol caused by excitotoxicity22,23. Activated calpain 
cleaves cytoskeletal proteins, such as α -II spectrin and results in the accumulation of α -II spectrin and 
formation of inclusions located in motor neurons20. Inhibition of calpain via expression of its endoge-
nous inhibitor, calpastatin, slowed degeneration of SOD1G93A motor neurons23.
Since multiple pathways for neuronal death are involved in the development and maintenance of this 
disease, an effective multi-target approach may be required to treat ALS10. Additionally, ALS treatment 
can only be given after disease onset, because there are no specific predictors, clinical diagnosis, or bio-
markers4. Lots of pharmacologic therapies used in both ALS clinical trials and stringent testing have been 
unsuccessful24. These failures at pre-clinical or clinical stage may attribute to the treatment’s inability to 
target more than one neuronal death pathway, resulting in an incomplete or ineffective blocking of motor 
neuron cell loss and ALS disease progression.
Adipose-derived stem cell conditioned media (ASC-CM), a biologically-derived reagent containing a 
multitude of neuroprotective and neurotrophic factors, such as brain-derived neurotropic factor (BDNF), 
nerve growth factor (NGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), 
and insulin-like growth factor-1 (IGF-1)25–28 was selected as ASC-CM has been previously shown to be 
neuroprotective by using both animal and cell culture models of neurodegeneration27,29,30. Our previous 
studies show that ASC-CM protected against hypoxia-ischemia-induced damage by blocking the activa-
tion of p38 MAPK27. NGF is a secreted growth factor in the central and peripheral nervous system. It 
is important in survival, growth and maintenance of specific types of neurons. The neurodegenerative 
disorders were due to the lack of hormones or growth factors31. NGF level was decreased in ALS dorsal 
spinal cord32. In this study, we evaluated the effectiveness of ASC-CM and investigated the role of NGF, 
a neurotrophic factor identified in the ASC-CM, in ASC-CM treatment for SOD1G93A mouse.
Materials and Methods
Animals. SOD1G93A heterozygous mice that overexpressing human SOD1-G93A mutation and wild 
type mice (WT) (all with B6SJL genetic background) were purchased form the Jackson Laboratory 
(Bar Harbor, ME, USA) and bred in the Animal Center of Indiana University School of Medicine. All 
animal procedures were performed in accordance with the protocols approved and authorized by the 
Institutional Animal Care and Use Committee at Indiana University School of Medicine. SOD1G93A mice 
were identified by PCR performance with DNA derived from tail tissue using a protocol provided by 
The Jackson Laboratory33.
Animal behavioral Assessment. As described in a previous paper33, behavioral assessment was per-
formed beginning at 90 days of age. SOD1G93A mice were randomly assigned to 5 different treatments of 
“ASC-CM”, “ASC-CM-NGF Ab”, “NGF Ab”, “NGF” or “vehicle”. SOD1G93A mice were tested twice a week 
on a Rotarod apparatus at a speed of 15 rpm (ENV-575M; Med Associates, Inc., St. Albans, VT, USA) 
and up to 3 trials per day. Mice that were unable to remain on the Rotarod for 10 minutes were deter-
mined as disease onset, this performance was further tested the following day under same parameters 
to further verify disease onset. Animal that could not right itself in 20 seconds when gently rolled on its 
side indicated the end stage (surrogate death time point). Mice were checked every morning for mortality 
and morbidity, and every afternoon for the righting reaction.
Poteomic analysis of the presence of neurotrophic factors in human ACS-CM. Human ASC 
secrete over 400 proteins into the medium during culture34. We detected interesting factors in ASC-CM 
using an antibody array (RayBio Human Growth Factor Array I, RayBiotech, GA)
Quantification of NGF by ELISA. NGF level in ASC-CM was measured using Human NGF ELISA 
kits (Abcam, Cambridge, MA, USA), an enzyme-linked immunosorbent assay (ELISA) kit, according to 
the manufacturer’s instructions35.
Animal Treatment. Human adipose-derived stem cell conditioned media (ASC-CM) was made as 
previously described29,36 and injected intraperitoneally (i.p.) at a volume of 200 μ l once daily. To neu-
tralize the activity of NGF, a polyclonal anti-NGF antibody (Abcam, Cambridge, MA, USA) was intro-
duced and tested for its specificity. No cross-reactivity has been detected after using it against VEGF, 
GDNF, IGF1 and BDNF.1 μ g/μ l of the antibody was incubated with ASC-CM at 5 μ g/ml overnight at 
4 °C28,37. NGF antibody neutralized ASC-CM treated mice group (ASC-CM-NGF Ab) received 200 ul 
ASC-CM-NGF antibody once daily. Additionally, as controls, the NGF Ab group daily received 5 μ g/ml 
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NGF antibody in 200 μ l Basal Media Eagle (BME), the NGF group daily had 200 pg/ml human NGF 
(R&D systems, Minneapolis, MN, USA) in 200 μ l BME, and the vehicle group mice were injected with 
200 μ l BME. One daily dose of ASC-CM, NGF antibody neutralized ASC-CM, NGF antibody, NGF or 
BME was given until a humane death endpoint for survival studies, and 3 or 7 days after onset for bio-
chemical and immunohistochemical studies.
Western Blot. Western blot analysis was performed with tissue lysates as previously described33,38 
after 3 or 7 days of ASC-CM or BME treatment. Radio-immunoprecipitation assay (RIPA) buffer and 
protease inhibitor (Roche Diagnostics Corp., Indianapolis, IN, USA) was used to homogenize spinal 
cord samples. 15 μ g/well of protein was loaded onto a 4–12% Bis-Tris gel, electrophoresed, then trans-
ferred to nitrocellulose membrane (Hybond N; Amersham Biosciences, Piscataway, NJ, USA). Blots were 
probed with rabbit polyclonal primary antibody against pp38 (1:1000; Millipore, Temecula, CA, USA), 
mouse monoclonal antibody against glial fibrillary acidic protein (1:1000, GFAP; Millipore), rabbit pol-
yclonal antibody against ionized calcium binding adaptor molecule 1 (1:1000, Iba-1; Wako Chemicals 
USA, Inc., Richmond, VA, USA), and goat polyclonal antibody against α -II spectrin (1:200, Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, USA) followed by horseradish peroxidase-conjugated secondary 
antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). Finally, visualized through utilizing 
enhanced chemiluminescence (Amersham Biosciences, Piscataway, NJ, USA), band intensities were 
quantitated by densitometric analysis (ImageJ, http://rsbweb.nih.gov/ij/).
Immunohistochemistry. Mice were anesthetized and perfusion-fixed with 4% paraformaldehyde 
(PFA) after treatments with ASC-CM or BME. PFA-fixed and paraffin embedded spinal cords were sec-
tioned (15 μ m) serially via the lumber enlargement and immunostained with anti-microtubule-associated 
protein 2 antibody (1:1000, MAP2; Millipore), then followed by a biotinylated anti-mouse IgG 
antibody (Sigma-Aldrich Corp.). Sections were visualized under the microscope after applying 
3,3′ -diaminobenzidine (DAB) substrate solution. A 40x objective light microscope (Nikon, Japan) was 
used to count large motor neurons in the ventral horn of the lumbar spinal cord39,40. 6–8 sections of 
each lumbar were counted. Data was reported as number of motor neurons per section as previously 
described33,41.
Statistical Analysis. One-way analysis of variance (ANOVA) was used for statistical analyses and 
comparisons for the differences between groups. All data are expressed as mean ± standard error of the 
mean (SEM). Differences between two means were considered significant when p was equal or less than 
0.05.
Results
Neurotrophic factors in ASC-CM. We tested interesting neurotrophic factors in ASC-CM by using 
a Human Growth Factor Antibody Array (containing 41 growth factor antibodies). Image showed the 
presence of NGF, VEGF, GDNF, IGF-1 in human ASC-CM. BDNF was detected in human ASC-CM by 
using enzyme-linked immunosorbent assay (ELISA) kit (Chemicon, Temecula, CA, USA)27.
ASC-CM significantly reduced disease progression and increased life span of SOD1G93A mice, 
while NGF antibody attenuated this effect. SOD1G93A mice were treated with ASC-CM from dis-
ease onset to a humane death endpoint. The duration from disease onset to death was measured. Data 
was reported as number of days of post-onset survival (Fig. 1A). The SOD1G93A mice given ASC-CM had 
increased post-onset survival times (31.6 ± 4.1 days, n = 5; ***p < 0.005) as compared to vehicle-treated 
mice (16.1 ± 1.6 days, n = 7). Interestingly, NGF antibody neutralized ASC-CM didn’t affect post-onset 
survival times (13.4 ± 2.7 days, n = 5) as compared to vehicle-treated mice. ASC-CM treated mice 
also had significantly longer lifespans (138.8 ± 3.1 days, n = 5, Fig.  1B) versus the vehicle counterparts 
(124.4 ± 1.5 days, n = 7) and as expected, NGF antibody attenuated this effect (121.7 ± 1.2, n = 5). As 
controls, we treated NGF Ab group mice and NGF group mice with 5 μ g/ml NGF antibody and 200 pg/
ml NGF, respectively and did not observe any effects of the NGF antibody and NGF on post-onset 
survival (14.6 ± 3.8 days, 18.0 ± 3.2 days vs. 16.1 ± 1.6 days) and lifespans (125.3 ± 5.8 days, 120.1 ± 3.9 
days vs. 124.4 ± 1.5 days).
ASC-CM increased the number of motor neurons in the lumbar spinal cord. A positive corre-
lation was observed between extended survival time of ASC-CM treated SOD1G93A mice and the preven-
tion of motor neuron loss. Changes in motor neuron number at 7 days following onset were analyzed in 
cross-sections of the lumbar spinal cords of SOD1G93A mice (Fig. 2A). BME-treated control mice showed 
a marked (***p < 0.005) loss of motor neurons in the ventral horn of the lumbar spinal cord versus WT 
control (7.8 ± 0.84 and 21.9 ± 0.79, respectively; Fig. 2B), but this loss was inhibited by ASC-CM treat-
ment (15.9 ± 2.0, p < 0.01 vs. vehicle). Although there was still significant motor neuron loss (p < 0.05) 
compared to age-matched and wild type mice, this loss was not as severe in the vehicle group (Fig. 2B).
Administration of ASC-CM had no effect on mouse SOD1wild type and mutant human SOD1G93A 
expression in SOD1G93A mice spinal cords. Studies have shown that the transgene copy number 
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(copies of the transgene with the G → A at position 93, human mutant form of SOD1) affects survival 
of the SOD1G93A mouse9. In order to determine if ASC-CM has an effect on SOD1 gene expression, 
immunoblot analyses were performed on spinal cord homogenates after 7 days of ASC-CM treatment 
Figure 1. Treatment with ASC-CM extends post-onset survival and lifespan of SOD1G93A mice. 
Symptomatic SOD1G93A mice were given daily ASC-CM, NGF depleted ASC-CM treatment or vehicle until 
endpoint. Duration of disease is reported as days of post-onset survival and measured by days between 
disease onset and humane death endpoint. Lifespan is the number of days from birth to the humane death 
endpoint. Symptomatic mice treated with ASC-CM daily (n = 5) had a significant increased survival time 
as compared to vehicle treated SOD1G93A mice (n = 7). The averages of post-onset survival time were 
significantly increased in mice given ASC-CM compared to vehicle. ASC-CM-treated mice with disease 
onset (n = 5) had a significant lifespan extension when compared to vehicle treated SOD1G93A mice (n = 7), 
but NGF antibody neutralized ASC-CM, NGF antibody, or NGF did not affect post-onset survival times 
(n = 5) (A). Increased post-onset survival time of ASC-CM treated mice was responsible for the significantly 
extended lifespan relative to vehicle mice. However, NGF antibody attenuated this effect in ALS mice. As 
controls, NGF antibody or NGF did not affect lifespans of mice (B). Statistical analysis was performed by 
using one-way ANOVA. ***p < 0.005 vs. vehicle.
Figure 2. ASC-CM 7-day treatment of SOD1G93A mice with disease showed increase number of motor 
neurons in the lumbar spinal. SOD1G93A mice were given ASC-CM or vehicle for 7 days after disease 
onset. Motor neurons in the spinal cord area were identified by immunoreactivity to MAP2 antibody. 
Representative images showed an increased number of MAP2-positive neurons in lumbar spinal cords of 
SOD1G93A mice treated with ASC-CM compared to vehicle. Scale bars: 100 μ m. (A). MAP2 immunoreactive 
images covering the entire cross-sectional area from6–8 lumbar spinal regions for each mouse were 
quantitated. With ASC-CM treatment, a higher number of motor neurons was observed in SOD1G93A mice 
with disease onset (n = 5) versus vehicle (n = 5). Wild type control data were generated from 4 mice 
(B). Experimental group data are presented as averages (± SEM) and statistical analyses were performed 
using one-way ANOVA. *p < 0.05; ***p < 0.005.
www.nature.com/scientificreports/
5Scientific RepoRts | 5:16953 | DOI: 10.1038/srep16953
(Fig.  3A). Band density measurements showed that levels of both wild type endogenous mouse SOD1 
(mSOD1WT) and mutated human SOD1 (hSOD1G93A) exhibited no differences with or without 7-day 
ASC-CM treatment (Fig. 3B). “Wild type/WT” mice express wild type endogenous mSOD1WT but does 
not carry the mutated hSOD1G93A transgene; “vehicle” and “ASC-CM” mice are the experimentally-treated 
SOD1G93A transgenic mice that express wild type endogenous mouse SOD1 (mSOD1WT) in addition to 
the hSOD1G93A transgene. Actin levels remain unchanged and assayed as loading controls for endogenous 
mSOD1WT. There were differences in endogenous mSOD1WT levels, which then served as an internal 
control for mutated hSOD1G93A expression.
Daily ASC-CM treatment reduced p38 MAP kinase phosphorylation in SOD1G93A mice spinal 
cords. Phosphorylated p38 (pp38) levels in spinal cords were examined at 3 days (Fig.  4A) and 7 
days (Fig. 4B) following disease onset with or without ASC-CM administration during that time period. 
In agreement with other reports using the SOD1G93A mouse17,19, p38 phosphorylation was elevated in 
SOD1G93A mice after disease onset at both 3 days (0.72 ± 0.008, p < 0.005 vs. wild type and ASC-CM; 
Fig. 4A) and 7 days post-onset (0.41 ± 0.05, p < 0.01 vs. wild type; Fig.4B). pp38 levels in spinal cords 
were significantly decreased with ASC-CM treatment for 3 days (0.36 ± 0.01, p < 0.005 vs. vehicle and 
wild type; Fig. 4A) and for 7 days (0.18 ± 0.07, p < 0.05 vs. vehicle; Fig.4B) as compared to the vehicle 
groups. Levels of pp38 in ASC-CM treated animals were higher than WT controls at 3 days (0.14 + 0.02, 
p < 0.005 vs. ASC-CM group; Fig.4A).
GFAP expression was reduced in the spinal cords of symptomatic SOD1G93A mice treated with 
ASC-CM. It has been demonstrated that motor neuron loss occurs partly through activated inflamma-
tory cells in the surrounding area42. Because treatment with ASC-CM showed significant neuroprotection 
of motor neurons possibly via anti-inflammatory mechanisms thus far, glial activation after treatment 
with ASC-CM was examined to further explore this possibility. Expression of GFAP was measured in 
the spinal cords of SOD1G93A mice after 3 days of treatment with ASC-CM or vehicle. Representative 
immunoblots demonstrated that there is significantly reduced GFAP expression with ASC-CM treatment 
(2.71 ± 0.08) versus vehicle (4.12 ± 0.07; ***p < 0.005; Fig. 5). The GFAP levels observed in the ASC-CM 
treated group were comparable to that of the wild type controls (2.20 ± 0.08).
Figure 3. Treatment with ASC-CM did not affect expression of endogenous mouse wild type SOD1 and 
mutated human SOD1 transgene in spinal cord. Wild type control (WT) and SOD1G93A mice (vehicle and 
ASC-CM) spinal cords were prepared as detailed in materials and methods. Levels of actin were unchanged 
and used as an internal loading control for endogenous mouse wild type SOD1 (mSOD1WT). There was 
no difference in mSOD1WT levels, which was the loading control for mutated human SOD1 (hSOD1G93A). 
After 7 days of ASC-CM treatment, there was no change in expression of either endogenous mSOD1WT or 
hSOD1G93A mice in symptomatic SOD1G93A mice. n = 3 per group.
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Figure 4. pp38 reduction was observed after 3 or 7 days of ASC-CM treatment in SOD1G93A mice spinal 
cords after disease onset. SOD1G93A mice with onset received ASC-CM or vehicle for 3 days or 7 days, 
while spinal cords were removed for Western blot. (A): (a) Representative immuoblots and (b) quantitation 
of band density showed reduced pp38 expression in SOD1G93A mice spinal cords after 3 days ASC-CM 
treatment versus BME treatment. (B): (a) Representative immunoblots and (b) densitometric quantitation 
demonstrated reduced pp38 expression in 7 days ASC-CM-treated mice compared to BME-treated mice. 
Unchanged total p38 levels were used as internal loading controls. Values are shown as mean density ± SEM 
and statistical analyses were performed using one-way ANOVA. *p < 0.05; **p < 0.01; ***p < 0.005; n = 3 per 
group.
Figure 5. 3-day treatment with ASC-CM showed reduced GFAP expression in the spinal cords of 
SOD1G93A mice after disease onset. Figure SOD1G93A mice with disease onset were given ASC-CM or 
vehicle for 3 days. Spinal cords were removed for immunoblot. Actin expression levels remained constant 
in all groups and were used as internal loading controls. (A) Representative immunoblots and (B) band 
quantitation demonstrated a decrease in spinal cord GFAP expression after 3-day ASC-CM treatment as 
compared to vehicle. Experiments were completed in triplicate with n = 3 per group. *p < 0.05; ***p < 0.005.
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Administration of ASC-CM to SOD1G93A mice with disease onset decreased CD11b expres-
sion in spinal cords. In order to further investigate glial activation after ASC-CM treatment, spinal 
cords were prepared for Western blot and examined for expression of CD11b, a glial marker found to 
be induced by neuroinflammation14. CD11b expression was observed at 3 days (Fig.  6A) and 7 days 
(Fig. 6B) after ASC-CM or vehicle treatment. 3 days of ASC-CM treatment demonstrated no differences 
in CD11b expression in all groups (group averages ± SEM: 0.073 ± 0.018 for wild type; 0.068 ± 0.012 for 
vehicle; 0.066 ± 0.018 for ASC-CM, Fig.  6A). However, 7 days of ASC-CM treatment demonstrated a 
significant decrease in CD11b expression in the spinal cord of ASC-CM-treated animals (0.109 ± 0.017, 
Fig.  6B)when compared to vehicle mice (0.251 ± 0.015 for vehicle, ***p < 0.005 versus wild type and 
ASC-CM), whose CD11b expression level was at a similar level to wild type mice (0.100 ± 0.005) after 
7 days.
ASC-CM treatment of symptomatic SOD1G93A mice resulted in decreased expression of α-II 
spectrin in spinal cords. ASC-CM’s effect on the calpain system in SOD1G93A mice was determined 
by measuring expression of α -II spectrin, a known cleavage target of calpain43. After 3 days following 
disease onset, activity of the Ca2+-activated protease, calpain, was increased in SOD1G93A mice spinal 
cords given vehicle(0.81 ± 0.002, n = 4, ***p < 0.005) as compared to wild type controls (0.10 ± 0.006, 
n = 3), consistent to a previous report20. Cleaved α -II spectrin was significantly decreased in SOD1G93A 
mice receiving ASC-CM treatment as compared to mice given vehicle (0.15 ± 0.026, n = 3, ***p < 0.005, 
Fig. 7). Levels of actin remained unchanged for all groups and were used as internal loading controls.
Discussion
This study was designed to confirm the effects of a biologically-derived reagent on an ALS animal 
model that is clinically relevant such that treatment was applied after disease onset was established in 
the widely used SOD1G93A mouse model8. The data collected from this study demonstrate the effective-
ness of ASC-CM treatment in prolonging post-onset survival and extending the lifespan of symptomatic 
SOD1G93A mouse. These results are in agreement with previous experiments from our laboratory, show-
ing that the treatment with ASC-CM is beneficial and protective of neurons in vivo during neuronal 
injury or challenge, such as in the hypoxic-ischemic rat neonatal brain27. The findings from this study 
Figure 6. CD11b expression in spinal cords of symptomatic SOD1G93A mice after 3 days or 7 days 
of ASC-CM treatment. SOD1G93A mice were given 3 days or 7 days of ASC-CM treatment or vehicle 
upon disease onset. Spinal cords were processed Western blot as described in Experimental Procedures. 
Unchanged actin levels in all groups were used as internal loading controls. (A) (a) The representative 
immunoblots and (b) band densities that were measured showed no change in spinal cord CD11b expression 
after 7 days of ASC-CM treatment. (B) (a) The representative immunoblots and (b) band quantitation 
demonstrated a decrease in spinal cord CD11b expression after 7 days of ASC-CM treatment as compared to 
vehicle. n = 3, ***p < 0.005.
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and the previous in vivo studies suggest that ASC-CM has the potential as a therapeutic for neuronal 
degeneration.
Although the etiology of sporadic ALS is currently unknown, through the use of animal models 
and correlation with neuropathological findings from human ALS patients, several key mechanisms of 
neuronal death have been proposed to disrupt normal motor neuron function and lead to their degen-
eration. Current studies implicate glutamate-induced excitotoxicity, mitochondrial dysfunction, oxida-
tive stress, neuroinflammation, aberrant axonal transport systems, endoplasmic reticulum (ER) stress, 
inhibition of proteosomal function, compromised blood-brain barrier, and abnormal protein aggrega-
tion44. There is much debate as to which processes contribute towards disease etiology and which events 
are secondary to the established disease state. This presents ALS drug development with difficulties as 
neuropathology-specific targeting of treatment may be ineffective.
Despite the mechanistic uncertainties underlying events leading to ALS neuropathologic changes, 
treatments like ASC-CM may prove to be beneficial as they are able to block or modify several neuronal 
death pathways due to the heterogeneity in their composition. ASC-CM has been found to contain a 
multitude of neurotrophic factors that could be beneficial for the diseased motor neuron27. It was shown 
that neurotrophic factors may play a critical role in protecting or delaying motor neuronal death in ALS 
mice45. In this study, neurotrophic factors in ASC-CM could access affected neurons in CNS by either 
directly crossing the blood brain barrier46,47 or going through the retrograde transport mechanism45,46. 
Additionally, since motor neuronal death in ALS mice showed a distal–proximal gradient, it is also pos-
sible some neurotrophic factors in ASC-CM increased lifespan of ALS mice by directly protecting the 
neuromuscular junctions in peripheral45. Furthermore, in order to overcome the short half-life of poly-
peptides in ASC-CM peripherally, we i.p. injected ASC-CM daily until the end of experiments48,49. Here, 
after post-onset treatment with ASC-CM peripherally, symptomatic SOD1G93A mice have significant pro-
longation of post-onset survival times, which translated into an overall extension of lifespan. However, 
since many neurotrophic factors existing in ASC-CM may exert neuroprotective effects together as a 
neuroprotective mixture body27, deletion of single factor may fully remove its neuroprotective effects. 
In this study, we test this hypothesis by targeting the NGF contained in ASC-CM50. As predicted, NGF 
neutralized ASC-CM did not elongate the post-onset survival times and lifespan of SOD1G93A mice.
Additionally, the lengthening of post-onset lifespan following ASC-CM administration was correlated 
with markedly increased numbers of motor neuron survival in the spinal cord lumbar area. Further 
examinations at the cellular level determined that the increase in motor neuron survival after ASC-CM 
treatment was accompanied by decreased expression of glial activation markers and phosphorylated 
p38 MAP kinase, which are important components of the neuroinflammation pathway51 contributing to 
neuronal death in the spinal cords of SOD1G93A mice17. Other data from this study shows lower levels of 
cleaved α -II spectrin, which is a known substrate of both calpain and caspase-352,53. Decreased cleavage 
of α -II spectrin in the spinal cords of ASC-CM-treated SOD1G93A mice may indicate that calpain has 
protective effects against glutamate-induced neuronal apoptosis20,21,23.
Figure 7. ASC-CM treatment for 3 days decreased α-II spectrin cleavage in symptomatic SOD1G93A 
mice. SOD1G93A mice were given ASC-CM or vehicle for 3 days. Western blot analysis was done to measure 
α -II spectrin. Unchanged actin levels expression were used as internal loading controls. (A) Representative 
immunoblots and (B) quantitation of band densities revealed a decrease in cleaved α -II spectrin expression 
at 3 days post-onset when ASC-CM treatment was given. Wild type, n = 5; vehicle, n = 3; ASC-CM, n = 4. 
***p < 0.005.
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Growing evidence has shown that NGF induces neuronal survival with low-affinity binding to the p75 
neurotrophin receptor (p75NTR)54. Additionally, it was shown that NGF-induced neuroprotection against 
OGD insult by inhibiting OGD-induced p38 activation55 and against UV neurotoxicity by inhibiting 
calpain activity56. Furthermore, increased production of NGF in central nervous system (CNS) during 
diseases is able to suppress inflammation by switching the immune response to an anti-inflammatory57. 
Therefore, it is quite possible that NGF induced neuroprotection in ASC-CM-treated SOD1G93A mice 
via neuroprotection, inhibition of p38 and calpain, as well as anti-inflammation. It would be interest-
ing to investigate by using appropriate models how NGF protects motor neurons in ASC-CM-treated 
SOD1G93A mice and whether glial activation or inflammatory processes play important roles in this neu-
roprotective process.
Taken together, this study demonstrated that ASC-CM provides significant neuroprotection in the 
SOD1G93A mouse model of ALS and extendsSOD1G93A mice life span. NGF in ASC-CM plays a significant 
role in this neuroprotection. This protective ability may associate with the preservation of motor neurons 
and inflammatory pathway inhibition in the spinal cord. This study establishes the therapeutic potential 
of this agent for treating ALS. Additionally, ASC-CM also holds great promise as potential therapies for many 
other neurodegenerative diseases due to the validated beneficial effects in many experimental models.
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